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Interference with the alternative splicing of apoptotic factors offers an innovative and specific mech-
anism to target malignant cells. In this issue of Chemistry & Biology, Zhou et al. [1] report on the
regulation of the alternative splicing of Bcl-x pre-mRNA in response to emetine, a potent protein
synthesis inhibitor, as well as define a major player in the signaling mechanism.Apoptosis is a mechanism by which
cells execute endogenous programs
of cell death, often in response to ad-
verse external or internal signals. It is
now well known that the inactivation
or deregulation of apoptotic pathways
can lead to tumor development and
chemotherapy resistance. The rela-
tionship between apoptosis and can-
cer was originally established in 1988
whenDavid Vaux and colleagues dem-
onstrated that the bcl-2 gene specifi-
cally inhibits the death of B cells in fol-
licular lymphoma. Several years later,
Stanley Korsmeyer, David Hockenb-
ery, and colleagues characterized
bcl-2 as a ‘‘brake’’ gene, acting to pre-
vent apoptosis. Since then, a number
of proteins related to Bcl-2 have been
grouped into a collective Bcl-2 family,
which has been widely implicated in
regulating apoptotic machinery.
One member of the Bcl-2 family,
Bcl-x, is a well-established modulator
of apoptosis induced by a multitude of
stimuli [2–4]. The regulation of Bcl-x ex-
pression is acomplexmechanism involv-
ing both transcriptional and posttran-
scriptional processes [2, 5]. In regards
to posttranscriptional processing, the
bcl-x gene produces two main iso-
forms via alternative splicing: the anti-
apoptotic Bcl-xL protein and the proa-
poptotic Bcl-xS variant [5]. Bcl-xS is
produced via activation of an alterna-
tive upstream 50 splice site in exon
2 of the Bcl-x pre-mRNA transcript,
whereas Bcl-xL is produced when the
entirety of exon 2 is included in thema-
ture mRNA transcript. In a biological
context, this mechanism of alternativesplicing has consequences in cell sig-
naling. For example, numerous studies
have shown that overexpression of the
Bcl-xL isoform in cells elicits resistance
to apoptotic stimuli and cooperates
with oncogenic factors (e.g., c-Myc) in
tumorigenesis [6–8]. In addition, many
cell types spontaneously resistant to
chemotherapeutic agents exhibit in-
creased levels of Bcl-xL [9, 10]. In con-
trast, the scientific literature has shown
that expression of the antagonistic
splice variant, Bcl-xS, will induce apo-
ptosis, alleviate multidrug resistance,
and overcome Bcl-xL overexpression
to confer apoptotic sensitivity [5, 11,
12]. Importantly, relatively low Bcl-xS
expression can overcome Bcl-xL block-
age of apoptosis [3, 4]. The mechanism
by which Bcl-xS confers sensitivity to
apoptotic stimuli is largely unstudied
as Bcl-xS has been shown not to com-
pete with Bcl-xL for binding to other
apoptotic proteins [3, 4].
In recent years, the alternative pre-
mRNA splicing of apoptotic factors
has been given greater attention in can-
cer research. For example, both Sharp
and colleagues and Krainer and col-
leagues have demonstrated that RNA
trans-factors can act as oncogenes
[13, 14]. It has also been discovered
that splice variants of a variety of spe-
cific signaling factors have an oppo-
site/dominant-negative function, and
dysregulation of alternative splicing is
also a common characteristic of human
cancer. Since the normal control of the
apoptotic process is often disturbed in
transformed cells, scientists such as
Zhou and colleagues are now focusedChemistry & Biology 14, December 2007 ª2on understanding how the production
of proapoptotic and antiapoptotic
splice variants are regulated, and un-
covering new ways to interfere with
splicing control, specifically the alter-
native splicing of Bcl-x pre-mRNA.
Several previous reports have dem-
onstrated that the alternative splicing
of Bcl-x pre-mRNA can be regulated
by small molecules such as ceramide,
as well as receptor agonists such as
Il-6 and Il-1a [5, 15, 16]. In this issue of
Chemistry & Biology, Zhou and col-
leagues report on the role of emetine
on the alternative pre-mRNA splicing
of Bcl-x [1]. In efforts to identify addi-
tional small molecules responsible
for regulating Bcl-x splicing, Zhou and
colleagues screened 1040 FDA ap-
proved drugs and compounds using
RT-PCR analysis in C33A cells, a cervi-
cal cancer cell line. Emetine, a potent
protein synthesis inhibitor, was demon-
strated to downregulate Bcl-xL mRNA
with a concomitant increase in the level
of Bcl-xS mRNA in a dose- and time-
dependent manner. Interestingly, cyclo-
heximide also regulated alternative
splicing of exon 2 in the bcl-x gene.
After confirming the emetine and cy-
cloheximide-mediated effect on Bcl-x
splicing, the authors proceeded to
perform cell-based experiments to de-
termine phosphorylation dependency.
C33A and PC3 cells were treated
with calyculin A and okadaic acid,
two phosphatase inhibitors. Results
demonstrated that treatment of C33A
and PC3 cells with calyculin A, an in-
hibitor of both protein phosphatase-1
(PP1) and protein phosphatase-2A007 Elsevier Ltd All rights reserved 1313
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PreviewsFigure 1. Known Signal Transduction Pathways and RNA Trans-Factors That
Regulate the Alternative Splicing Bcl-X Pre-mRNA(PP2A), completely blocked the eme-
tine effects onBcl-x splicing in contrast
tookadaicacid, a selectivePP2A inhib-
itor. Thus, Zhou and colleagues con-
cluded that emetine exerts its effect
on Bcl-x splicing via protein phospha-
tase-1. This method of action is similar
to what has been described for ceram-
ide and the chemotherapeutic agent
gemcitabine. Specifically, treatment
of A549 lung adenocarcinoma cells
with cell-permeable ceramide or gem-
citabine downregulated Bcl-xL mRNA
levels with a concomitant increase in
the levels of Bcl-xS mRNA in a dose-
and time-dependent manner [5]. Simi-
larily, PP1 was also demonstrated to
mediate the ceramide-induced effect
on Bcl-x splicing [5]. The studies by
Zhou and colleagues not only extend
these findings, but also demonstrate
the translatability of this system to cer-
vical and prostate cancer.
These studies by Zhou and col-
leagues have largely defined the signal1314 Chemistry & Biology 14, Decembertransduction pathway leading to the
activation of the Bcl-xS 5
0 splice site
in response to protein synthesis inhib-
itors such as emetine. These are excit-
ing studies, and future studies by Zhou
and colleagues aswell as other labora-
tories will hopefully pursue the iden-
tification of both the apoptotic and
prosurvival pathways of signal trans-
duction that regulate the fate of a
cell, and thus, a whole organism. In
this regard, two recent studies by
Sette and colleagues [17] and Chabot
and colleagues [18] are also beginning
to shed light on possible survival path-
ways, which regulate this RNA splicing
mechanism. All of these studies now
present an intriguing question for the
scientific community to answer: Does
ceramide, emetine, and gemcitabine
affect the 50 splice site selection of
Bcl-x pre-mRNA via a direct apoptotic
signaling mechanism or indirectly by
‘‘shutting down’’ constitutive survival
pathways (Figure 1)?2007 ª2007 Elsevier Ltd All rights reservedREFERENCES
1. Boon-Unge, K., Yu, Q., Zou, T., Zhou, A.,
Govitrapong, P., and Zhou, J. (2007).
Chem. Biol. 14, this issue, 1386–1392.
2. Boise, L.H., Gottschalk, A.R., Quintans, J.,
and Thompson, C.B. (1995). Curr. Top.
Microbiol. Immunol. 200, 107–121.
3. Minn, A.J., Boise, L.H., and Thompson,
C.B. (1996). Genes Dev. 10, 2621–2631.
4. Sumantran, V.N., Ealovega, M.W., Nunez,
G., Clarke, M.F., and Wicha, M.S. (1995).
Cancer Res. 55, 2507–2510.
5. Chalfant, C.E., Rathman, K., Pinkerman,
R.L., Wood, R.E., Obeid, L.M., Ogretmen,
B., and Hannun, Y.A. (2002). J. Biol.
Chem. 277, 12587–12595.
6. Pena, J.C., Rudin, C.M., and Thompson,
C.B. (1998). Cancer Res. 58, 2111–2116.
7. Pena, J.C., Thompson, C.B., Recant, W.,
Vokes, E.E., and Rudin, C.M. (1999). Can-
cer 85, 164–170.
8. Naik, P., Karrim, J., and Hanahan, D.
(1996). Genes Dev. 10, 2105–2116.
9. Gardner, C.R. (2004). Expert Rev. Antican-
cer Ther. 4, 1157–1177.
10. Kim, R. (2005). Biochem. Biophys. Res.
Commun. 333, 336–343.
11. Sumantran, V.N., Lee, D.S., Woods Igna-
toski, K.M., Ethier, S.P., and Wicha, M.S.
(2000). Neoplasia 2, 251–260.
12. Massiello, A., Salas, A., Pinkerman, R.L.,
Roddy, P., Roesser, J.R., and Chalfant,
C.E. (2004). J. Biol. Chem. 279, 15799–
15804.
13. Cheng, C., and Sharp, P.A. (2006). Mol.
Cell. Biol. 26, 362–370.
14. Karni, R., de Stanchina, E., Lowe, S.W.,
Sinha, R., Mu, D., and Krainer, A.R.
(2007). Nat. Struct. Mol. Biol. 14, 185–193.
15. Li, C.Y., Chu, J.Y., Yu, J.K., Huang, X.Q.,
Liu, X.J., Shi, L., Che, Y.C., and Xie, J.Y.
(2004). Cell Res. 14, 473–479.
16. Pollock, A.S., Turck, J., and Lovett, D.H.
(2003). FASEB J. 17, 203–213.
17. Paronetto, M.P., Achsel, T., Massiello, A.,
Chalfant, C.E., and Sette, C. (2007).
J. Cell Biol. 176, 929–939.
18. Revil, T., Toutant, J., Shkreta, L., Garneau,
D., Cloutier, P., and Chabot, B. (2007). Mol.
Cell Biol. 27, 8431–8441.
